Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311330084> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4311330084 endingPage "991" @default.
- W4311330084 startingPage "985" @default.
- W4311330084 abstract "Aim To assess the in-market use of Saxenda (liraglutide 3.0 mg) and Victoza (liraglutide 1.2 mg/1.8 mg) according to approved indications and posology. Materials and methods This retrospective, non-interventional study was conducted at 41 sites from December 2016 to May 2019. Via medical record review, physicians at each site identified patients who had been prescribed Saxenda (Italy) or Victoza (Italy/Germany) within the 24 months following launch in each country. Pseudonymized data were abstracted on patient and site characteristics, indication for the prescription, posology and duration of usage. Adherence to the approved indications and posology, and to the Saxenda stopping rule, were assessed. No formal statistical analysis was performed. Results A total of 440 patients were prescreened and 225 (51.1%) were enrolled (Saxenda: N = 75, all in Italy; Victoza: N = 75 in Italy and N = 75 in Germany). In all, 96% (72/75) of Saxenda prescriptions, and 98.7% (148/150) of Victoza, were in accordance with the approved indications. Among the 40 patients treated with Saxenda for 16 weeks or longer, only two (5.0%) were confirmed as non-adherent to the stopping rule. Adherence could not be assessed in 23 (57.5%) patients because of missing body weight measurements. Conclusions This retrospective, real-world post-authorization safety study provides reassurance that Saxenda and Victoza are primarily used according to the approved European label, thus their real-world utilization did not raise safety concerns." @default.
- W4311330084 created "2022-12-25" @default.
- W4311330084 creator A5021456308 @default.
- W4311330084 creator A5027433747 @default.
- W4311330084 creator A5039838502 @default.
- W4311330084 creator A5040809526 @default.
- W4311330084 creator A5086346174 @default.
- W4311330084 date "2023-01-23" @default.
- W4311330084 modified "2023-10-18" @default.
- W4311330084 title "Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study" @default.
- W4311330084 cites W1798757189 @default.
- W4311330084 cites W1970656852 @default.
- W4311330084 cites W1978191819 @default.
- W4311330084 cites W1993070711 @default.
- W4311330084 cites W1994320162 @default.
- W4311330084 cites W2015788437 @default.
- W4311330084 cites W2061549173 @default.
- W4311330084 cites W2071835038 @default.
- W4311330084 cites W2137352234 @default.
- W4311330084 cites W2152835319 @default.
- W4311330084 cites W2160001758 @default.
- W4311330084 cites W2170606300 @default.
- W4311330084 cites W2307508267 @default.
- W4311330084 cites W2555053373 @default.
- W4311330084 cites W2791728731 @default.
- W4311330084 cites W4213437296 @default.
- W4311330084 cites W807162506 @default.
- W4311330084 doi "https://doi.org/10.1111/dom.14945" @default.
- W4311330084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36514273" @default.
- W4311330084 hasPublicationYear "2023" @default.
- W4311330084 type Work @default.
- W4311330084 citedByCount "0" @default.
- W4311330084 crossrefType "journal-article" @default.
- W4311330084 hasAuthorship W4311330084A5021456308 @default.
- W4311330084 hasAuthorship W4311330084A5027433747 @default.
- W4311330084 hasAuthorship W4311330084A5039838502 @default.
- W4311330084 hasAuthorship W4311330084A5040809526 @default.
- W4311330084 hasAuthorship W4311330084A5086346174 @default.
- W4311330084 hasBestOaLocation W43113300841 @default.
- W4311330084 hasConcept C108759981 @default.
- W4311330084 hasConcept C126322002 @default.
- W4311330084 hasConcept C134018914 @default.
- W4311330084 hasConcept C167135981 @default.
- W4311330084 hasConcept C194828623 @default.
- W4311330084 hasConcept C195910791 @default.
- W4311330084 hasConcept C2426938 @default.
- W4311330084 hasConcept C2777180221 @default.
- W4311330084 hasConcept C2781308992 @default.
- W4311330084 hasConcept C38652104 @default.
- W4311330084 hasConcept C41008148 @default.
- W4311330084 hasConcept C555293320 @default.
- W4311330084 hasConcept C71924100 @default.
- W4311330084 hasConcept C98274493 @default.
- W4311330084 hasConceptScore W4311330084C108759981 @default.
- W4311330084 hasConceptScore W4311330084C126322002 @default.
- W4311330084 hasConceptScore W4311330084C134018914 @default.
- W4311330084 hasConceptScore W4311330084C167135981 @default.
- W4311330084 hasConceptScore W4311330084C194828623 @default.
- W4311330084 hasConceptScore W4311330084C195910791 @default.
- W4311330084 hasConceptScore W4311330084C2426938 @default.
- W4311330084 hasConceptScore W4311330084C2777180221 @default.
- W4311330084 hasConceptScore W4311330084C2781308992 @default.
- W4311330084 hasConceptScore W4311330084C38652104 @default.
- W4311330084 hasConceptScore W4311330084C41008148 @default.
- W4311330084 hasConceptScore W4311330084C555293320 @default.
- W4311330084 hasConceptScore W4311330084C71924100 @default.
- W4311330084 hasConceptScore W4311330084C98274493 @default.
- W4311330084 hasIssue "4" @default.
- W4311330084 hasLocation W43113300841 @default.
- W4311330084 hasLocation W43113300842 @default.
- W4311330084 hasOpenAccess W4311330084 @default.
- W4311330084 hasPrimaryLocation W43113300841 @default.
- W4311330084 hasRelatedWork W1997914857 @default.
- W4311330084 hasRelatedWork W2412318721 @default.
- W4311330084 hasRelatedWork W3148396094 @default.
- W4311330084 hasRelatedWork W3199023559 @default.
- W4311330084 hasRelatedWork W3204549863 @default.
- W4311330084 hasRelatedWork W3209802769 @default.
- W4311330084 hasRelatedWork W4205529031 @default.
- W4311330084 hasRelatedWork W4283591600 @default.
- W4311330084 hasRelatedWork W4286457321 @default.
- W4311330084 hasRelatedWork W4317620497 @default.
- W4311330084 hasVolume "25" @default.
- W4311330084 isParatext "false" @default.
- W4311330084 isRetracted "false" @default.
- W4311330084 workType "article" @default.